Dr. Robert Nolan - Non Exec Director

Bob has over 30 years experience in big pharma, from 1989 to end 2004 as Director of Global Licensing at AstraZeneca. In this role he managed major product licensing transactions aimed at acquiring world-wide rights to the products of other companies. He led these negotiations and also performed the initial technical evaluation of the opportunities (with the assistance of other team members). Bob worked with a broad variety of partner companies ranging from virtual biotech start-ups to multi-billion global entities with the considerations involved in these projects ranging from the single $millions to in excess of $300 million.

In 2002 Bob became a member of the Board of NeuTec Pharma plc, which was recently acquired by Novartis AG for £305M.

During his career, Bob has dealt with a broad range of therapeutic areas covering central nervous system, infection, cardiovascular, cancer, gastrointestinal and respiratory. Between 1979-1989 he was in charge of Natural Products Research at ICI Pharmaceuticals, seeking novel anti-bacterial and anti-cancer agents from various fermentation sources. During 7 years at Sandoz (now Novartis) in Vienna, Bob became group leader working on the mechanism of antibiotic action, and was a member of the Research Strategic Planning Committee.

Bob is a non-executive director of f2g Ltd and Epistem Ltd, and is a founder and Chairman of Cardiff Protides Ltd and of Cardiff Biologicals Ltd. He also provides licensing consultancy services to the LG Life Sciences Corporation of Korea.

Bob gained his Ph.D. in biochemistry from King’s College, London, and completed two post-doctoral fellowships in the US at Dartmouth Medical School and MIT. He speaks fluent German and reasonable French and Italian, is an active member of the Licensing Executives Society having been on their Healthcare Committee, and occasionally lectures on issues related to licensing.